4th ACTC | Advances in Circulating Tumor Cells | Liquid Biopsy: Latest Advances and Future Challenges



Platinum Sponsors

Menarini Silicon Biosystems logo

Menarini Silicon Biosystems, develops techno­logies and products that help researchers understand the biological complexity of disease through the study of single cells. The company’s DEPArray NxT is the only image-based digital cell-sorting and isolation platform that enables clinical researchers to conduct molecular analyses on live or fixed cells with single-cell precision. Thanks to the acquisition of the CELLSEARCH® Circulating Tumor Cell System in 2017, the company now provides an end-to-end workflow solution for the enumeration, isolation, and molecular charac­terization of CTCs from a simple blood test in the clinical research setting.

Gold Sponsors

Agena Bioscience Logo

We Empower Precision Medicine – Agena Bioscience is dedicated to advancing the impact of genomics in healthcare and precision medicine. Our highly sensitive and cost-effective mass spectrometry-based platform, the MassARRAY® System, is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, and clinical research. We are a leader dedicated to enabling clinical laboratories worldwide to deliver affordable targeted genomic testing

ANGLE logo

ANGLE is a UK and US based medical diagnostic company. ANGLE’s Parsortix technology enables the capture and harvest of circulating tumor cells (CTCs) from patient blood. Genetic and protein analysis of CTCs from this ‘liquid biopsy’ has the potential to enable personalized cancer care and improve clinical outcome.

Silver Sponsors

Gilupi nano medizin logo

Advancing diagnostic procedures for precision medicine. People are individual – and so are their diseases. Especially in cancer, the variability of the tumors leads to strong differences in the respective therapy response. Integrating molecular diagnostics into clinical routine opens up the possibility of precisely characterizing patients and their disease and eventually identifying the most effective therapy. Furthermore, cancer cells can change or evolve over time. This poses additional challenges to the treatment and suggests a continuous monitoring of disease progression. GILUPI‘s goal is to develop a portfolio of diagnostic products for personalized medicine based on our technology platform, the GILUPI CellCollector®.

RareCyte logo

RareCyte is an innovative life science company that has developed technologies for the analysis of rare single cells in blood and tissue. Our end-to-end integrated platform for rare cell analysis includes consumables, instrumentation, analysis software, and cell retrieval capabilities that enable advances in CTCs, liquid biopsy, tissue imaging for oncology, immuno-oncology, single-cell analysis, and more.

Stilla technologies logo


ALS Automated Lab Solutions logo
Bio Molecular Systems logo

Bio Molecular Systems is an Australian company established in 2010 and comprising of the founders from the former Corbett Life Sciences company. BMS is the manufacturer of the Mic, the world’s first Magnetic Induction Cycler for qPCR using a patented magnetic induction technology to heat samples very fast. This means qPCR results in less than 25 min. Fast. Accurate. Compact and Connective are just some of the key features that set Mic apart from all other qPCR instruments. Recently we launched Myra, a very small qPCR setup robot. In fact it is the world’s first robot that can actually see.

Luminex logo

At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We serve the needs of our customers in diverse markets including clinical diagnostics, pharmaceutical drug discovery, life science research, immunology, and personalized medicine. Our goal is to transform global healthcare with innovative instruments and assays that deliver cost-effective, rapid results to clinicians and researchers.

Servier logo

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.176 billion euros in 2018, Servier employs 22,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) into Research and Development, and all profits are used for further development. Corporate growth at Servier is driven by our continuous pursuit of innovation in five areas of excellence: cardiovascular and immune-inflammatory diseases, neuropsychiatric disorders, cancer and diabetes., as well as by its activities in high-quality generic drugs.

VyCAP logo

4th ACTC | Advances in Circulating Tumor Cells | Liquid Biopsy: Latest Advances and Future Challenges